TY - CHAP M1 - Book, Section TI - Cytotoxic and Antimetabolic Agents A1 - Honaker, Jeremy S. A1 - Korman, Neil J. A2 - Kang, Sewon A2 - Amagai, Masayuki A2 - Bruckner, Anna L. A2 - Enk, Alexander H. A2 - Margolis, David J. A2 - McMichael, Amy J. A2 - Orringer, Jeffrey S. Y1 - 2019 N1 - T2 - Fitzpatrick's Dermatology, 9e AB - AT-A-GLANCECytotoxic and antimetabolic agents are used in dermatology to treat serious, life-threatening, and recalcitrant disease.Methotrexate and azathioprine are commonly used in dermatology whereas thioguanine, hydroxyurea, cyclophosphamide, chlorambucil, and liposomal doxorubicin are occasionally used.Methotrexate is U.S. Food and Drug Administration (FDA) approved for treatment of psoriasis and advanced mycosis fungoides, whereas cyclophosphamide is FDA approved for advanced mycosis fungoides only, and liposomal doxorubicin is approved for AIDS-related Kaposi sarcoma; other uses of the agent in this chapter occur on an “off-label” basis.Cytotoxic and antimetabolic agents act through inhibition and/or interruption of the cell cycle.Side effects and complications with these potentially dangerous medications are numerous, and close clinical followup and laboratory evaluation is necessary.Cytotoxic agents used in dermatology, as well as those initiated for other purposes, may yield distinctive cutaneous eruptions and cutaneous sequelae. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - dermatology.mhmedical.com/content.aspx?aid=1161344313 ER -